Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: effectiveness and safety.

Vassiliou V.

Clin Oncol (R Coll Radiol). 2013 May;25(5):290-7. doi: 10.1016/j.clon.2013.01.008. Epub 2013 Mar 5. Review.

PMID:
23466465
[PubMed - indexed for MEDLINE]
2.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
[PubMed - indexed for MEDLINE]
3.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

PMID:
21942303
[PubMed - indexed for MEDLINE]
Free Article
4.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
[PubMed - indexed for MEDLINE]
Free Article
5.

Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

Clin Ther. 2012 Jun;34(6):1334-49. doi: 10.1016/j.clinthera.2012.04.008. Epub 2012 May 11.

PMID:
22578308
[PubMed - indexed for MEDLINE]
6.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
[PubMed - indexed for MEDLINE]
7.

[Inhibition of RANK ligand to treat bone metastases].

Body JJ.

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835. Review. French.

PMID:
24158618
[PubMed - indexed for MEDLINE]
8.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
[PubMed - indexed for MEDLINE]
Free Article
9.

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K.

Ann Oncol. 2012 Dec;23(12):3045-51. doi: 10.1093/annonc/mds175. Epub 2012 Jul 31.

PMID:
22851406
[PubMed - indexed for MEDLINE]
Free Article
10.

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.

Clin Cancer Res. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.

PMID:
22893628
[PubMed - indexed for MEDLINE]
Free Article
11.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.

Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Clin Breast Cancer. 2012 Aug;12(4):247-58. doi: 10.1016/j.clbc.2012.04.001. Epub 2012 Jun 12.

PMID:
22694824
[PubMed - indexed for MEDLINE]
13.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

J Med Econ. 2013;16(1):19-29. doi: 10.3111/13696998.2012.719054. Epub 2012 Sep 5.

PMID:
22870908
[PubMed - indexed for MEDLINE]
14.

Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Carter JA, Joshi AD, Kaura S, Botteman MF.

Pharmacoeconomics. 2012 May;30(5):373-86. doi: 10.2165/11631390-000000000-00000. Review.

PMID:
22500986
[PubMed - indexed for MEDLINE]
15.

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.

Gomez-Veiga F, Ponce-Reixa J, Martinez-Breijo S, Planas J, Morote J.

Actas Urol Esp. 2013 May;37(5):292-304. doi: 10.1016/j.acuro.2012.09.001. Epub 2012 Dec 13. Review. English, Spanish.

PMID:
23246105
[PubMed - indexed for MEDLINE]
16.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
[PubMed - indexed for MEDLINE]
17.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
[PubMed - indexed for MEDLINE]
18.

Optimal management of metastatic bone disease.

Major P.

Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. Epub 2007 Sep 4. Review.

PMID:
17804294
[PubMed - indexed for MEDLINE]
19.

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.

Rolfo C, Raez LE, Russo A, Reguart N, Campelo RG, Bronte G, Papadimitriou K, Silvestris F.

Expert Opin Biol Ther. 2014 Jan;14(1):15-26. doi: 10.1517/14712598.2013.843667. Epub 2013 Oct 28. Review.

PMID:
24161019
[PubMed - indexed for MEDLINE]
20.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

PMID:
23049248
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk